Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imatinib Mesylate

FDA-approved product (capsule, oral), marketed as Gleevec, Imatinib Mesylate, Imkeldi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Dermatofibrosarcoma protuberans
  • Gastrointestinal stromal tumor
  • Hypereosinophilic syndrome
  • Lymphoblastic lymphoma
  • Myelodysplastic/myeloproliferative disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    NCT06124157 · start 2025-05-30

    Registered record
    Registry ID
    NCT06124157
    Conditions
    B Acute Lymphoblastic Leukemia
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-30
    Completion
    2030-12-01
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol +17 more
    PhasePhase 2
    Registry statusRecruiting

  • GIST Oral Paclitaxel(Liporaxel)

    NCT06326346 · start 2024-11-20

    Registered record
    Registry ID
    NCT06326346
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Liporaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-20
    Completion
    2027-03-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionLiporaxel
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

    NCT06087263 · start 2024-06-18

    Registered record
    Registry ID
    NCT06087263
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-06-18
    Completion
    2034-07-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRegorafenib
    PhasePhase 2
    Registry statusActive not recruiting

  • 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

    NCT05385549 · start 2022-09-07

    Registered record
    Registry ID
    NCT05385549
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Imatinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-09-07
    Completion
    2030-04-30
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionImatinib Mesylate
    PhasePhase 2
    Registry statusRecruiting

  • The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

    NCT04422678 · start 2020-06

    Registered record
    Registry ID
    NCT04422678
    Conditions
    COVID-19
    Interventions
    Imatinib Mesylate; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-06
    Completion
    2020-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionImatinib Mesylate; Standard of Care
    PhasePhase 3
    Registry statusUnknown

  • Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

    NCT04193553 · start 2020-01-17

    Registered record
    Registry ID
    NCT04193553
    Conditions
    Gastro Intestinal Stromal Tumour
    Interventions
    Lenvatinib; Placebo; Best supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-17
    Completion
    2024-04-26
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastro Intestinal Stromal Tumour
    InterventionLenvatinib; Placebo; Best supportive care
    PhasePhase 2
    Registry statusCompleted

  • Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

    NCT05387330 · start 2018-04-01

    Registered record
    Registry ID
    NCT05387330
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    ELISA kit
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-04-01
    Completion
    2021-12-28
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionELISA kit
    PhaseNot recorded
    Registry statusCompleted

  • LAM Pilot Study With Imatinib Mesylate

    NCT03131999 · start 2018-01-23

    Registered record
    Registry ID
    NCT03131999
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    Imatinib Mesylate 400Mg Capsule; Placebo - Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-01-23
    Completion
    2019-03-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    InterventionImatinib Mesylate 400Mg Capsule; Placebo - Capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

    NCT02924714 · start 2017-01

    Registered record
    Registry ID
    NCT02924714
    Conditions
    Gastrointestinal Stromal Tumor
    Interventions
    Discontinuation of imatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Suspended
    Start
    2017-01
    Completion
    2022-11
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor
    InterventionDiscontinuation of imatinib
    PhaseNot applicable
    Registry statusSuspended

  • Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

    NCT02881086 · start 2016-08

    Registered record
    Registry ID
    NCT02881086
    Conditions
    Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    Interventions
    Rituximab; Nelarabine; PEG-Asparaginase; Cranial irradiation; Imatinib; Idarubicin; Dexamethasone; Cyclophosphamide; Fludarabine; Vincristine; Mercaptopurine; VP16; Daunorubicin (DNR); Methotrexate; Stem cell transplantation; Cytarabine; Vindesine; Adriamycin; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08
    Completion
    2024-12
    Enrolment
    1,023

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    InterventionRituximab; Nelarabine; PEG-Asparaginase; Cranial irradiation +15 more
    PhasePhase 3
    Registry statusCompleted

  • CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

    NCT02401815 · start 2015-03-06

    Registered record
    Registry ID
    NCT02401815
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    CGT9486; Pexidartinib; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03-06
    Completion
    2020-05-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionCGT9486; Pexidartinib; Sunitinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

    NCT02115672 · start 2014-11

    Registered record
    Registry ID
    NCT02115672
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    BL-8040
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2014-11
    Completion
    2018-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionBL-8040
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

    NCT02204722 · start 2014-10-13

    Registered record
    Registry ID
    NCT02204722
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    600mg/day of Imatinib; 400mg/day of Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-10-13
    Completion
    2018-01-09
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    Intervention600mg/day of Imatinib; 400mg/day of Imatinib
    PhasePhase 4
    Registry statusTerminated

  • Treatment-free Remission Accomplished With Dasatinib in Patients With CML

    NCT02268370 · start 2014-10

    Registered record
    Registry ID
    NCT02268370
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2021-10
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionDasatinib
    PhasePhase 2
    Registry statusUnknown

  • RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

    NCT01188889 · start 2013-09

    Registered record
    Registry ID
    NCT01188889
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    RAD001; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionRAD001; Imatinib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn